Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) is set to release its earnings data before the market opens on Thursday, August 3rd. Analysts expect Regeneron Pharmaceuticals to post earnings of $8.66 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $8.44 EPS for the quarter, beating the consensus estimate of $7.71 by $0.73. Regeneron Pharmaceuticals had a return on equity of 20.41% and a net margin of 33.81%. The business had revenue of $3.16 billion for the quarter, compared to analyst estimates of $2.92 billion. On average, analysts expect Regeneron Pharmaceuticals to post $34 EPS for the current fiscal year and $35 EPS for the next fiscal year.
Regeneron Pharmaceuticals Price Performance
Shares of NASDAQ REGN opened at $730.96 on Thursday. Regeneron Pharmaceuticals has a 1-year low of $563.82 and a 1-year high of $837.55. The company has a market cap of $80.19 billion, a price-to-earnings ratio of 19.86, a price-to-earnings-growth ratio of 2.26 and a beta of 0.22. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.45 and a quick ratio of 4.67. The stock’s 50-day moving average is $739.00 and its two-hundred day moving average is $758.32.
Analyst Ratings Changes
A number of brokerages have recently commented on REGN. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $915.00 to $875.00 in a research report on Wednesday, June 28th. Barclays lowered their price target on Regeneron Pharmaceuticals from $915.00 to $888.00 in a research report on Wednesday, June 28th. JPMorgan Chase & Co. lifted their price target on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, March 31st. 888 reissued a “maintains” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 5th. Finally, Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $880.00 to $927.00 in a research note on Friday, May 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $868.25.
Insider Activity
In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $735.42, for a total value of $73,542.00. Following the transaction, the director now directly owns 18,847 shares in the company, valued at $13,860,460.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $735.42, for a total value of $73,542.00. Following the transaction, the director now owns 18,847 shares in the company, valued at approximately $13,860,460.74. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Marion Mccourt sold 250 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $710.09, for a total transaction of $177,522.50. Following the completion of the transaction, the executive vice president now owns 20,303 shares in the company, valued at approximately $14,416,957.27. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 700 shares of company stock worth $506,753. Company insiders own 8.83% of the company’s stock.
Institutional Trading of Regeneron Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mather Group LLC. purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $222,000. EP Wealth Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $214,000. Rodgers Brothers Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $210,000. Wall Street Access Asset Management LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth about $209,000. Finally, Arvest Trust Co. N A purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $209,000. 89.21% of the stock is owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Regeneron Pharmaceuticals wasn’t on the list.
While Regeneron Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.
